Nargiza Parpieva

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · New England Journal of Medicine · 2022 · 352 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · The Lancet Respiratory Medicine · 2023 · 96 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +12

Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

S.K. Abidi, Jay Achar, M.M. Assao Neino et al. · European Respiratory Journal · 2019 · 88 citations · Full text

Public Health, Pharmacotherapy, Clinical Epidemiology +16

Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study

Jamshid Gadoev, Damin Asadov, Mirzagolib Tillashaykhov et al. · PLoS ONE · 2015 · 59 citations · Full text

Public Health, Health Sciences, Adolescent Health +12

Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

Shona Horter, Beverley Stringer, Jane Greig et al. · BMC Infectious Diseases · 2016 · 34 citations · Full text

Public Health, Community Health, Clinical Medicine +16